Publication at Faculty of Medicine in Pilsen, Third Faculty of Medicine |
2012
Abstract
Authors present an overview of registry concerned on expensive drugs in lung cancer patients in Czech republic. There are those drugs - erlotinib, pemetrexed, gefitinib and bevacizumab.
Treatment responses, time to progression and overal survival of patients, as well as side effects of such therapy are registered. Clinical registry support actual data for clinicians and for health care pagers.